IDH2 and central nervous system cancer: For glioblastomas, cIMPACT and the new WHO (2021) Classification recommended the use of EGFR amplification, TERT, and chromosome 7+/10− as criteria for diagnosis of molecular glioblastoma in IDH wild-type adult gliomas, which do not show diagnostic histological features like necrosis and microvascular proliferation (1, 47).